Evidence map›Paper›PMID 42738841›Full record

ArticleCells2026

Endothelial Cells Offer a Better Option than Smooth Muscle Cells for the Treatment of Ischemic Limb Disease.

Akazha Green, Hanyu Zhang, Bing Bo, Bijay Guragain, Yalin Wu, Yuhua Wei, Jianyi Zhang, Lei Ye

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Akazha GreenDepartment of Biomedical Engineering, University of Alabama at Birmingham, Volker Hall, 1670 University Boulevard, Birmingham, AL 35233, USA.ORCID 0009-0003-1768-6379
Hanyu ZhangDepartment of Biomedical Engineering, University of Alabama at Birmingham, Volker Hall, 1670 University Boulevard, Birmingham, AL 35233, USA.
Bing BoDepartment of Biomedical Engineering, University of Alabama at Birmingham, Volker Hall, 1670 University Boulevard, Birmingham, AL 35233, USA.
Bijay GuragainDepartment of Biomedical Engineering, University of Alabama at Birmingham, Volker Hall, 1670 University Boulevard, Birmingham, AL 35233, USA.
Yalin WuDepartment of Biomedical Engineering, University of Alabama at Birmingham, Volker Hall, 1670 University Boulevard, Birmingham, AL 35233, USA.ORCID 0009-0003-8772-6671
Yuhua WeiDepartment of Biomedical Engineering, University of Alabama at Birmingham, Volker Hall, 1670 University Boulevard, Birmingham, AL 35233, USA.
Jianyi ZhangDepartment of Biomedical Engineering, University of Alabama at Birmingham, Volker Hall, 1670 University Boulevard, Birmingham, AL 35233, USA.
Lei YeDepartment of Biomedical Engineering, University of Alabama at Birmingham, Volker Hall, 1670 University Boulevard, Birmingham, AL 35233, USA.

Funding

Project 3 - Role of Proline Metabolism in Regulation of Mammalian Cardiomyocyte ProliferationP01HL160476 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Hesham Sadek · 2022 to 2026
$13.1M
Supplement of HL131017: Myocardial remuscularization by cardiac patch delivery of epicardial FSTL1 and CCND2 overexpressing cardiomyocytesR01HL131017 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SERPOOSHAN, VAHID, ZHANG, JIANYI · 2016 to 2025
$5.8M
Deciphering the Neonatal Cardiac Regenerative Potential and Regulators in Large AnimalsR01HL149137 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SADEK, HESHAM, ZANGI, LIOR · 2019 to 2022
$2.5M
National Heart Lung and Blood Institute P01HL160476 and R01HL131017, and R01HL149137NHLBI NIH HHS P01 HL160476NHLBI NIH HHS R01 HL131017NHLBI NIH HHS R01 HL149137
6 · The paper itself

Abstract

Peripheral arterial disease (PAD) is estimated to affect at least 10 million people in the United States and over 200 million individuals worldwide. The clinical manifestations of PAD range from impaired mobility and pain with activity to chronic limb-threatening ischemia with risk of eventual tissue loss. Despite the significant global prevalence and debilitating consequences of the disease, non-option patients remain largely undertreated. Recognizing that ECs are well-known for their therapeutic role in enhancing perfusion and neovascularization in mouse models of critical limb ischemia, we hypothesize that a synergy of ECs with SMCs may achieve better recovery of perfusion and neovascularization than ECs or SMCs alone. In this study, we compared the therapeutic efficacy of hiPSC-ECs, hiPSC-SMCs, and hiPSC-ECs + hiPSC-SMCs for the treatment of critical limb disease using a NOD-SCID mouse model of hind limb ischemia (HLI). A total of 1 × 10

Indexed as

Endothelial CellsHindlimbIschemiaMyocytes, Smooth MusclePeripheral Arterial DiseaseAngiogenesisAnimalsDisease Models, AnimalHumansInduced Pluripotent Stem CellsMiceMice, Inbred NODMice, SCIDNeovascularization, Physiologiccell differentiationendothelial cellshuman induced pluripotent stem cellsischemic limb diseasesmooth muscle cells

Identifiers

PMID42738841
PMCPMC13565117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.